Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells

Cancer Science

Volumn 101, Issue 7, 2010, Pages 1661-1669

  Cavaliere, Carla ^a   Corvigno, Sara ^a   Galgani, Mario ^a   Limite, Gennaro ^a   Nardone, Agostina ^a   Veneziani, Bianca Maria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CD24 ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMESTANE; HERMES ANTIGEN; MESSENGER RNA; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL INTERACTION; CELL SUBPOPULATION; COCULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; ENZYME INHIBITION; EPITHELIUM CELL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MESENCHYME CELL; PRIORITY JOURNAL; STROMA CELL; TREATMENT RESPONSE;

ANDROSTENEDIONE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 77954654471     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01593.x     Document Type: Article

References (57)

1. Ince TA, Richardson AL, Bell GW. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007, 12:160-70.
2. Dunning AM, Dowsett M, Healey CS. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96:936-45.
3. Sorlie T, Tibshirani R, Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-23.
4. Sotiriou C, Neo SY, McShane LM. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-8.
5. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2005, 8:1609-10.
6. Santen RJ, Brodie H, Simpson ER. History of aromatase: saga of an important biologic mediator and therapeutic target. Endocr Rev 2009, 30:343-75.
7. Suzuki T, Miki Y, Ohuchi N, Sasano H. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 2008, 15:270-7.
8. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993, 170:31-5.
9. Suzuki T, Darnel AD, Akahira JI. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 2001, 86:2250-7.
10. Hudelist G, Singer CF, Manavi M. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 2003, 80:353-61.
11. Dowsett M, Houghton J, Iden C. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-26.
12. Shipitsin M, Campbell LL, Argani P. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-73.
13. Honeth G, Bendahl PO, Ringnér M. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53.
14. Godar S, Ince TA, Bell GW. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134:62-73.
15. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
16. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-37.
17. Sleeman KE, Kendrick H, Ashworth A. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 2006, 8:R7.
18. Durst B, Sorg RV, Röder G. The influence of hormones on CD44 expression in endometrial and breast carcinomas. Oncol Rep 2001, 8:987-93.
19. Veneziani BM, Criniti V, Cavaliere C. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Mol Cancer Ther 2007, 6:3091-100.
20. Tallarida RJ. Interactions between drugs and occupied receptors. Pharmacol Ther 2007, 113:197-209.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-8.
22. Hurt EM, Kawasaki BT, Klarmann GJ. CD44(+)CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-65.
23. Ponti D, Costa A, Zaffaroni N. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-11.
24. Johnston S, Pippen J, Pivot X. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-46.
25. Salhab M, Reed MJ, Al Sarakbi W. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Treat 2006, 99:155-62.
26. Sasano H, Anderson TJ, Silverberg SG. The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 2005, 95:35-9.
27. Prall OW, Rogan EM, Musgrove EA. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998, 18:4499-508.
28. Altucci L, Addeo R, Cicatiello L. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-24.
29. Arpino G, Wiechmann L, Osborne CK. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29:217-33.
30. Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009, 8:18-22.
31. Nicholson RI, McClelland RA, Robertson JF. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6:373-87.
32. Shou J, Massarweh S, Osborne CK. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-35.
33. Osborne CK, Bardou V, Hopp TA. Role of the estrogen receptor coactivator AIB1(SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-61.
34. Massarweh S, Osborne CK, Jiang S. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006, 66:8266-73.
35. Banerjee S, Smith IE, Folkerd L. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005, 16:1632-8.
36. Ellis MJ, Tao Y, Young O. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-25.
37. Kaufman B, Mackey JR, Clemens MR. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-37.
38. Nicholson RI, Hutcheson IR, Knowlden JM. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-54S.
39. Schiff R, Osborne CK. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 2005, 7:205-11.
40. Massarweh S, Osborne CK, Creighton CJ. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-33.
41. Cristofanilli M, Valero V, Mangalik A. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR_) metastatic breast cancer (MBC). J Clin Oncol 2008, 26:44s. (suppl; abstr 1012)
42. Osborne K, Neven P, Dirix L. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):S107.
43. Allred DC, Wu Y, Mao S. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008, 14:370-8.
44. Park SY, Gönen M, Kim HJ. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010, 120:636-44.
45. Park SY, Lee HE, Li H. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010, 16:876-87.
46. Frogne T, Laenkholm AV, Lyng MB. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009, 11:R11.
47. Singer CF, Gschwantler-Kaulich D, Fink-Retter A. HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer. J Cancer Res Clin Oncol 2009, 135:807-13.
48. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358(13):1409-11.
49. Korkaya H, Paulson A, Iovino F. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-30.
50. Wang P, Wen Y, Han GZ. Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators? Br J Pharmacol 2009, 158:1796-807.
51. De Placido S, De Laurentiis M, Carlomagno C. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003, 9:1039-46.
52. Benz CC, Scott GK, Sarup JC. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24:85-95.
53. Hurtado A, Holmes KA, Geistlinger TR. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663-6.
54. Pacilio C, Germano D, Addeo R. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res 1998, 58:871-6.
55. Bindels EM, Lallemand F, Balkenende A. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 2002, 21:8158-65.
56. Reis-Filho JS, Savage K, Lambros MB. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006, 19:999-1009.
57. Wang Y, Dean JL, Millar EK. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008, 68:5628-38.